Imfinzi found to improve survival in small cell lung cancer - PharmaTimes

Imfinzi found to improve survival in small cell lung cancer  PharmaTimes

AstraZeneca has announced that its monoclonal antibody, Imfinzi (durvalumab), was found to improve overall survival at interim analysis in the Phase III ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Respirology | APSR Respiratory Medicine Journal